结直肠癌奥沙利铂化疗相关脾肿大。

Splenomegaly during oxaliplatin-based chemotherapy for colorectal carcinoma.

机构信息

Department of Surgery, Colorectal Cancer Center, Konkuk University Medical Center, Konkuk University School of Medicine, 143-729, 4-12 Hwayang-dong, Gwangjin-gu, Seoul, Republic of Korea.

出版信息

Anticancer Res. 2012 Aug;32(8):3357-62.

PMID:22843915

Abstract

AIM

The aim of this study was to evaluate changes in splenic size and platelet counts, in patients with colorectal cancer during oxaliplatin based chemotherapy, and to determine their clinical significance.

PATIENTS AND METHODS

The prospectively archived records of 50 patients with colorectal cancer that received oxaliplatin-based chemotherapy were reviewed.

RESULTS

Thirty-eight men and 12 women, of median age 58 (range 35-77) years, were enrolled. Median spleen volume ratios were 1.3-fold after 6 cycles and 1.9-fold after 12 cycles. The incidence of splenomegaly was 30% after 6 cycles and 67% after 12 cycles, and of thrombocytopenia was 70% after 6 cycles, 82% after 9 cycles, and 80% after 12 cycles. Thrombocytopenia was found to be related to splenomegaly, and this pattern was notable after 6 cycles of chemotherapy.

CONCLUSION

Splenic enlargement and reduction in platelet counts were common during chemotherapy. Furthermore, these changes were found to occur rapidly after 6 cycles of chemotherapy.

摘要

目的

本研究旨在评估结直肠癌患者在奥沙利铂为基础的化疗过程中脾脏大小和血小板计数的变化，并确定其临床意义。

患者和方法

回顾性分析了 50 例接受奥沙利铂为基础化疗的结直肠癌患者的前瞻性存档记录。

结果

入组患者 38 例男性和 12 例女性，中位年龄为 58（范围 35-77）岁。6 个周期后脾脏体积比中位数为 1.3 倍，12 个周期后为 1.9 倍。6 个周期后脾肿大的发生率为 30%，12 个周期后为 67%，血小板减少症的发生率为 6 个周期后为 70%，9 个周期后为 82%，12 个周期后为 80%。血小板减少症与脾肿大有关，这种模式在化疗 6 个周期后尤为明显。